The monoclonal antibody J591 is being investigated as therapy for patients with prostate
cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin). The study
is an open-label, non-randomized phase II study for patients with documented hormone
refractory prostate cancer.
In this Phase II, open label study, patients will receive daily low-dose subcutaneous rIL-2
(1.2 x 10^6 IU/m^2/day) continuously beginning on day 1. Patients will receive 3 weeks of
IL-2, and on day 22 will receive the monoclonal antibody huJ591 via I.V. (25mg/m^2) for 3
consecutive weeks. Il-2 will be continued for 2 additional weeks for a total of 8 weeks.
The 8 week regimen will constitute 1 cycle of therapy. Patients who have responded to
therapy or have stable disease will be eligible for additional cycles of therapy.
- Histologic diagnosis (recent or remote) of prostate adenocarcinoma
- Metastatic or recurrent carcinoma of the prostate defined by abnormal CT or MRI
and/or abnormal bone scan and/or rising PSA.
- Rising PSA on 3 serial determinations over a period of > or equal to 2 weeks.
- PSA > or equal to 1.0 at the time of entry.
- If patient is being treated with an LHRH analog the drug: a. must be maintained for
the duration of the study or b. must be terminated > or equal to 10 weeks prior to
entry (for 28 day depot preparations) or 24 weeks (for 3 month depot preparations).
- Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of entry.
- History of CNS metastasis, and/or history of seizure and/or stroke.
- Lab values: ANC<1500/mm3; platelet count<100,000/mm3; serum creatinine>2.0; SGOT>2 x
normal; bilirubin (total)>1.5; serum calcium> or equal to 11.5.
- Active serious infection not controlled by antibiotics.
- Active angina pectoris or NYHA Class III-IV.
- Karnofsky Performance Status <60.
- Life Expectancy < 3 months.
- Age< 21y.
- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
hematological organ systems which might preclude completion of this study or
interfere with determination of causality of any adverse effects experienced in this
- Untreated thyroid disease, with the exception of treated and stable hyperthyroidism
or hypothyroidism for at least 4 weeks prior to entry.